EMA's PRAC recommends new restrictions on domperidone & diacerein
This article was originally published in Scrip
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has recommended that products containing domperidone should remain on the market but with additional restrictions to reduce the risk of serious cardiac side-effects. The committee has also advised restrictions on diacerein-containing drugs in order to manage the risks of severe diarrhea and liver disorders, reversing its earlier recommendation to suspend the drug.
You may also be interested in...
Participants in a recent webinar looked at how the coronavirus is changing the way we look at clinical trials and whether new EU COVID-19 guidance might hold lessons for future approaches to study design.
There is much talk around the importance of clinical trials in finding new treatments and vaccines for COVID-19 patients, but observational studies in clinical practice also have a vital role to play, including the impact on pregnant women.
Switzerland’s medicines agency has cleared Ferring’s carbetocin for preventing uterine haemorrhage under the Marketing Authorization for Global Health Products (MAGHP) procedure, which is intended to accelerate the approval of new products in low- and middle-income countries.